Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.95USD
7:22pm BST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.95
Open
$0.98
Day's High
$0.98
Day's Low
$0.95
Volume
35,199
Avg. Vol
49,666
52-wk High
$2.83
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

DelMar Pharmaceuticals Reports Q3 Loss Per Share Of $0.13
Thursday, 17 May 2018 

May 17 (Reuters) - DelMar Pharmaceuticals Inc ::DELMAR PHARMACEUTICALS ANNOUNCES THIRD QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.13.  Full Article

Delmar Pharmaceuticals Q2 Loss Per Share $0.14
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Delmar Pharmaceuticals Inc ::DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.14.  Full Article

Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing.  Full Article

Delmar Pharmaceuticals names Saiid Zarrabian interim CEO
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer.Jeffrey Bacha, cofounder of Co, will continue in role as president and in newly created position of chief operating officer​.Zarrabian and Bacha will continue to serve on company's board of directors​.  Full Article

DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - DelMar Pharmaceuticals Inc :DelMar Pharmaceuticals Inc <<>> CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing.  Full Article

DelMar Pharmaceuticals announces $10 million registered direct offering
Wednesday, 20 Sep 2017 

Sept 20 (Reuters) - DelMar Pharmaceuticals Inc ::Announces $10 million registered direct offering priced at-the-market.Entered into securities purchase agreements of an aggregate of 8 million shares of common stock at $1.25 per share​.  Full Article

Delmar Pharmaceuticals receives IND allowance from FDA
Monday, 18 Sep 2017 

Sept 18 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer.  Full Article

Delmar Pharmaceuticals initiates phase 2 clinical trial
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Delmar Pharmaceuticals Inc -:Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme.Delmar Pharmaceuticals- clinical trial will explore safety of chemoradiation with VAL-083 as alternative to standard-of-care temozolomide in patients.  Full Article

Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083
Monday, 24 Jul 2017 

July 24 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM.Delmar Pharmaceuticals Inc - trial is expected to open for enrollment in coming weeks at Sun Yat-Sen University Cancer Center (SYUCC) in Guangzhou.Delmar Pharmaceuticals Inc - HGRAC approved application to initiate phase 2 safety and efficacy study of its lead product candidate VAL-083.  Full Article

Delmar Pharmaceuticals reports completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory GBM
Tuesday, 18 Jul 2017 

July 18 (Reuters) - Delmar Pharmaceuticals Inc ::Delmar Pharmaceuticals announces completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory gbm.Delmar Pharmaceuticals Inc - Delmar anticipates initiation of additional centers and commencement of treatment under star-3 protocol in coming weeks.  Full Article

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM